B. Riley Securities: Reiterated CytoSorbents (CTSO.US) rating and adjusted from buy to buy rating, target price of $3.00.
CytoSorbents Analyst Ratings
Hold Rating on Cytosorbents Amid Regulatory Uncertainties and Mixed Clinical Results
CytoSorbents Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target
CytoSorbents Analyst Ratings
Cytosorbents Financial and Clinical Study Outlook: Maintaining a Hold Rating
CytoSorbents Holds Steady With Neutral Rating Amid Clinical and Financial Reassessments
HC Wainwright & Co. Downgrades CytoSorbents to Neutral, Lowers Price Target to $1
CytoSorbents Analyst Ratings
B. Riley Trims Price Target on Cytosorbents to $3 From $4, Maintains Buy Rating
Promising Financial Outlook and Potential Game-Changer Study Drive Buy Rating for Cytosorbents
CytoSorbents Analyst Ratings
Watching CytoSorbents; Hearing Zacks Small-Cap Research Sets $6 Price Target; Says CytoSorbents Reports 2nd Quarter 2023 Financial And Operating Results Which Showed Strong Product Revenue Growth And An Improved Cost Structure
HC Wainwright & Co. Reiterates Buy on CytoSorbents, Maintains $5.5 Price Target
CytoSorbents Analyst Ratings
H.C. Wainwright Reaffirms Their Buy Rating on Cytosorbents (CTSO)
HC Wainwright & Co. Reiterates Buy on CytoSorbents, Maintains $5.5 Price Target
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Cytosorbents (CTSO)
Cytosorbents (CTSO) Gets a Buy From H.C. Wainwright
No Data